🇺🇸 FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12275792

Antigen-binding proteins that activate the leptin receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12274747

Compositions and methods for treating cytokine release syndrome

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12268730

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12269889

Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lowe

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12269897

Anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12264343

TCRa homing endonuclease variants

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12264366

Genome-based methods for reducing cardiovascular risk

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12258627

Kelch domain containing 7B (KLHDC7B) variants and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12258412

Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12256720

Humanized dipeptidyl-peptidase IV (DPP4) animals

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12258597

Methods and compositions for therapeutic protein delivery

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12252520

Myosin 15 promoters and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12252530

Human antibodies to Fel d1 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12252544

Anti-CD63 antibodies, conjugates, and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12251440

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12250931

Genetically modified mouse with a humanized PNPLA3 gene and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12240908

N-terminal scFv multispecific binding molecules

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12240907

N-terminal scFv multispecific binding molecules

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12239687

Sustained release formulations using non-aqueous membrane emulsification

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12234460

Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12234277

Hydrophobic interaction chromatography for viral clearance

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12227740

CBLB endonuclease variants, compositions, and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12230364

Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burde

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12214023

Compositions and methods for expressing factor IX

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted